Major surgical procedure within 4 weeks prior to planned initiation of study therapy
Major surgery =<4 weeks before first dose of study drug or incomplete recovery from a prior major surgical procedure
Major surgical procedure within 28 days prior to the study.
Major surgical procedure within 4 weeks prior to Day 1
Prior major surgical procedure or radiation therapy within 4 weeks of the randomization
Subject who has undergone a major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of KHK2455 or is still recovering from prior surgery;
Prior radiation therapy or chemotherapy within 2 weeks or major surgical procedure within 4 weeks of the first dose of study treatment
Patients who have had radiotherapy or minor surgical procedure within 14 days, or major surgical procedure within 28 days prior to administration of first dose of study drug are not eligible; patients with inadequate recovery from prior surgical procedure are also not eligible
Major surgery within 4 weeks of the first dose of BVD-523; tumor embolization procedure or ablation procedure within 2 weeks of first dose of BVD-523
Major surgical procedure within 28 days prior to Day 1 of Cycle 1.
Must not have undergone a major surgical procedure < 4 weeks prior to registration
Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
Planned surgical procedure within the next 90 days
Major surgical procedure within 4 weeks prior study treatment initiation
Minor surgical procedure within 15 days of study Cycle 1 Day 1
Surgical procedure w/in 4 wks of starting study drug. Or pt has surgery-related complications to Grade ?1
Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
Any planned pleurodesis as part of the surgical procedure.
Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment\r\n* Placement of a stent or central venous access catheter (e.g., port or similar) is not considered a major surgical procedure and is therefore permitted
Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
Major surgical procedure (as defined by the Investigator) within 14 days prior to the start of study treatment
Patient has had a surgical procedure 4 weeks prior to TURBT or will have other surgical procedures performed at the time of TURBT or within 4 weeks after TURBT
Any major surgical procedure within 4 weeks of first study treatment
Minor surgical procedure within 7 calendar days prior to cycle 1 day 1
Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Concomitant medical problems that would place the patient at unacceptable risk for a major surgical procedure
Invasive surgical procedure within 28 days prior to study pre-registration
Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Major surgical procedure within 4 weeks of first study treatment
Major surgical procedure (as defined by the principal investigator [PI] or co-PIs within 28 days prior to the first dose of durvalumab and tremelimumab or still recovering from prior surgery
Major surgical procedure (e.g. laparotomy, bowel resection) 4 weeks prior to start of the study drug
Must have fully healed from any surgical procedure to be safe for lumbar puncture according to treating neurosurgeon and at least 14 days should have elapsed since the surgical procedure
Major surgical procedure within four weeks prior to administration of the first dose of ARQ 751 a. To be eligible for the study treatment, all surgical wounds must be fully healed and any surgery-related adverse events must recover to Grade ? 1.
previous unilateral thoracic surgical procedure or trauma
Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of MEDI4736 and tremelimumab or still recovering from prior surgery
Patients who have had any major surgical procedure within 14 days of day 1
Major surgical procedure within 21 days prior to enrollment
Major surgical procedure within 28 days of study enrollment, or anticipated while on study
Major surgical procedure within four weeks prior to administration of the first dose of study drug • To be eligible for study treatment, all surgical wounds must be fully healed and any surgery-related adverse events (AE) must recover to Grade ? 1
Patients who have had any major surgical procedure within 14 days of Day 1. BM biopsy is not considered a major surgical procedure.
For the purposes of this study, the procedure with the highest estimated risk of DSC (as predicted by the Surgical Risk Calculator) will be denoted at the time of first registration as the “index procedure” that will be performed during the “index surgery”
Status post \r\n* Elective (curative or palliative) major cancer surgery at the time of the index surgery (patient may have undergone more than one of these procedures) OR \r\n* Elective surgical procedure(s) listed as an option (i.e., CPT code) in the Surgical Risk Calculator webpage (patient may have undergone more than one of these procedures)\r\n** For the purposes of this study, the procedure that was performed with the highest estimated risk of DSC (as predicted by the Surgical Risk Calculator) will be denoted at the time of second registration as the “index procedure” performed during the “index surgery”
Status post elective surgical procedure(s) not listed as options in the Surgical Risk Calculator webpage
Patients with a major surgical procedure or other investigational agents within 30 days before study enrollment
Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
Patients who have had any major surgical procedure within 14 days of Day 1.
Patients less than 2 weeks post major surgical procedure (all surgical wounds must be fully healed). For the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia
Patients with non-healing surgical wounds; patients must be at least two weeks from a major surgical procedure, and surgical wounds must be completely healed
Optune device application start date must be at least 4 weeks (28 days) from central nervous system (CNS) surgical procedure; excluding ventriculoperitoneal (VP) shunts, endoscopic third ventriculostomy (ETV) for which treatment could start 10 days post procedure; non-CNS surgical procedures such as but not limited to central venous catheter insertion at the discretion of treating physician and study chair
Patients with prior Whipple's procedure.
Patients must have recovered from any surgical procedure before enrolling on this study
Subject has had a major surgical procedure and has not completely recovered within 28 days prior to the start of study treatment.
Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
Patients who have had a surgical procedure unrelated to the study within 14 days or major surgery within 1 month prior to the administration of the study drug
Major surgical procedure within 4 weeks prior to randomization. Patient must have recovered from all surgery-related complications.
Embolization procedure or ablation procedure to treat tumor within 4 weeks of first dose of STA-9090
Major surgical procedure (as defined by the treating physician) within 28 days prior to the first dose of durvalumab and tremelimumab or still recovering from prior surgery
Has not undergone any major surgical procedures for at least 4 weeks, with full healing of all surgical wounds
Non-study related minor surgical procedure =< 5 days, or major surgical procedure =< 21 days, prior to the first dose of rucaparib; in all cases, patients must be sufficiently recovered and stable before treatment administration
Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
Patients who have had any major surgical procedure within 14 days of day 1
Concomitant medical problems that would place the patient at unacceptable risk for a major surgical procedure
Major surgical procedure less than 4 weeks from start of protocol treatment
Major surgical procedure within 4 weeks of treatment
Major surgical procedure within 4 weeks prior to enrolment.
Subject is going through another surgical procedure (other than ileostomy or adhesiolysis) during the surgery.
Major surgical procedure within 4 weeks prior to Study Day 1
Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.
Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Major surgical procedure within 30 days prior to Day -31 or still recovering from prior surgery
Anticipate having a major surgical procedure during the course of the study.
Major surgical procedure (as defined by the investigator) within 30 days prior to Study Day 1 or incomplete recovery from any prior surgery.
Requires open spinal procedure or a percutaneous procedure without the use of image guidance
Patients who have had any major surgical procedure within 28 days prior to day 1
Major surgical procedure within 2 weeks prior to starting treatment; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
Has undergone chemotherapy within 4 weeks of the anastomosis procedure and/or radiation within 3 days of the anastomosis procedure
Major surgical procedure other than for diagnosis within 28 days prior to D1C1
Major surgical procedure within 21 days prior to the first dose of IP.
Major surgical procedure within 28 days prior to the first dose of Investigational Product;
Major surgical procedure other than for diagnosis within 4 weeks prior to randomization
Surgical axillary staging procedure prior to study procedure (with exception of FNA or core biopsy).
Major surgical procedure within 28 days prior to the first dose of Investigational Product
Planned/or anticipated major surgical procedure during the course of the study
Planned surgical procedure that can impact the conduct of the study
Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure
Major surgical procedure (as defined by the investigator) within 30 days prior to Day 1 or still recovering from prior surgery.
Radiotherapy or minor surgical procedure within 2 weeks, or major surgical procedure within 4 weeks prior to administration of first dose of study drug; inadequate recovery from prior surgical procedure
Major surgical procedure within 4 weeks
Major surgical procedure within 4 weeks (28 days) prior to enrollment (port placement is not considered a major surgical procedure)
Any major surgical procedure or radiation within 4 weeks of first study treatment
Patients less than 4 weeks post major surgical procedure (all surgical wounds must be fully healed); for the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia
Major surgical procedure within 28 days of day 1 of therapy
Major surgical procedure (including periodontal) within 4 weeks
Subject has had a major surgical procedure (other than a biopsy) within 14 days prior to the first dose of study drug, or one is planned during the course of the study.
Major surgical procedure (other than study related biopsy), or a major surgical procedure is planned to occur during the planned study duration
Subject has had a major surgical procedure (other than study-related biopsy) within 14 days prior to the first dose of study drug, or a major surgical procedure is planned to occur during the study.
Patients who have had any major surgical procedure within 14 days of day 1
Major surgical procedure within 30 days prior to the first dose of investigational product or still recovering from prior surgery
Radiation therapy or major surgical procedure within 4 weeks of the first dose.
Major surgical procedure within 4 weeks prior to Day 1
A major surgical procedure within 4 weeks prior to the planned first day of study drug dosing or a surgical procedure is planned during the course of the study.
Major surgery ?4 weeks before first dose of study drug, or incomplete recovery from a prior major surgical procedure
Major surgical procedure within 4 weeks prior to initiation of study treatment
Surgical procedure or clinically significant trauma within 2 weeks of first dose of study treatment
Major surgical procedure within 30 days prior to Day 1 or incomplete recovery from any prior surgery
History of major surgical procedure within 28 days prior to start of study treatment
Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization
Any major surgical procedure within 3 weeks prior to the first dose of study drug;
Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Surgical resection or major surgical procedure within 4 weeks prior to the start of SL-701, or stereotactic biopsy within 7 days prior to the start of SL-701.
Prior chemotherapy or a major surgical procedure within 3 weeks, or radiotherapy within 2 weeks prior to first study treatment
Major surgical procedure within 4 weeks prior to Day 1
Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration.
Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 1 month prior to first study drug administration.
Receiving an organ transplant during the same surgical procedure.
Occurrence of major intraoperative complications that require resuscitation or deviation from the planned surgical procedure.
Patients who have had a major surgical procedure within the past 6 weeks
Have had a loco-regional procedure for the treatment of hepatocellular carcinoma (such as a percutaneous, trans-arterial, or radio-ablative procedure) less than 4 weeks prior to beginning protocol therapy. Protocol therapy may begin a minimum of 4 weeks after such a procedure provided the following criteria are met:
Major surgical procedure within 90 days
Major surgical procedure within 4 weeks prior to study treatment
Major surgical procedure within 28 days prior to study enrollment
Major surgical procedure within 4 weeks prior to Day 1
Major surgical procedure within 4 weeks prior to Cycle 1, Day 1
Patients must be less than 4 months from the surgical procedure for this recurrence
Major surgical procedure(s) within previous 4 weeks prior to study enrollment
Major surgical procedure within 4 weeks of treatment
Patients who have had any major surgical procedure within 14 days of day 1
A major surgical procedure (other than study related biopsy), or a major surgical is planned to occur during the study
Surgical procedure where both arms are required to be tucked at the patient's side
Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Major surgical procedure within 21 days of first study treatment
Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure
>= 28 days elapsed from the last surgical procedure (including biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity)
Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure
Patient is within 2 months of a major surgical procedure
Undergone abdominal-perineal resection, Hartmann procedure, or other surgical procedure leaving the patient without a functioning rectum
Patients must be scheduled for a procedure capable of providing a definitive pathological diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either:\r\n* Upper endoscopy\r\n* Surgical esophagectomy
current surgical procedure is a revision surgery for implant failure or infection;
Planned surgical procedure
Definitive breast surgical procedure prior to enrollment.
Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
Major surgical procedure within 4 weeks of first study treatment
Major invasive surgical procedure occurring between the first treatment-eligible PET/CT examination and end of radiotherapy that would affect the treatment target region
Patients must be scheduled for a procedure capable of providing a definitive pathologic diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either upper endoscopy or surgical esophagectomy
Patient must have recovered from any surgical procedure before enrolling on this study
Patient must not require a major surgical procedure =< 21 days prior to beginning therapy
Patient must not require an intermediate surgical procedure =< 14 days prior to beginning therapy
Prior major surgical procedure or radiation therapy within specified period of the first dose of study treatment (with defined exception).
DYNAMIC COHORT: No clinical plan for biopsy or surgical procedure of known or suspected cancer
Patient must be able to tolerate a major surgical procedure based on clinical evaluation, status of their cancer, and any other underlying medical problems
Prior major surgical procedure or radiation treatment within 2 weeks of initiation of study treatment (not including limited radiation used for palliation of bone pain)
